RadNet, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>RadNet, Inc. has filed its 2023 10-K report detailing financial performance and business operations for the fiscal year ending December 31, 2023.</b>

AI Summary

RadNet, Inc. (RDNT) filed a Annual Report (10-K) with the SEC on February 29, 2024. RadNet, Inc. filed its 2023 Form 10-K on February 29, 2024, reporting on the fiscal year ending December 31, 2023. The filing covers financial data and operational details for RadNet, Inc. Key financial statement information and disclosures are included. The report details the company's business, risk factors, and management's discussion and analysis. Historical financial data and segment information are provided for the fiscal years 2023, 2022, and 2021.

Why It Matters

For investors and stakeholders tracking RadNet, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of RadNet's financial health, operational strategies, and potential risks, crucial for investors assessing the company's current standing and future prospects. The detailed financial statements and segment reporting offer insights into revenue streams and profitability across different business areas, aiding in the evaluation of growth drivers and market position.

Risk Assessment

Risk Level: — RadNet, Inc. shows moderate risk based on this filing. The filing is a standard annual report (10-K), which typically contains a broad range of information including financial performance, risk factors, and business operations, necessitating a medium-risk assessment due to the inherent complexity and potential for undisclosed material information.

Analyst Insight

Investors should review the detailed financial statements, risk factors, and management's discussion and analysis within the 10-K to understand RadNet's performance and outlook.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed period of report)
• 2024-02-29 — Filing Date (Filed as of date)

Key Players & Entities

• RadNet, Inc. (company) — Filer name
• 2023 (date) — Fiscal year end
• 2024-02-29 (date) — Filing date
• 10-K (document) — Form type
• Los Angeles (location) — Business address city
• DE (location) — State of incorporation

FAQ

Industry Context

RadNet, Inc. operates within the healthcare services sector, specifically focusing on medical diagnostic imaging. This industry is characterized by technological advancements, regulatory oversight, and evolving reimbursement models.

Regulatory Implications

The healthcare industry is subject to extensive regulation by government bodies such as the Centers for Medicare & Medicaid Services (CMS) and the Food and Drug Administration (FDA). These regulations impact service delivery, billing, and product approvals.

What Investors Should Do

1. Analyze RadNet's revenue segments and growth rates for FY2023, FY2022, and FY2021.
2. Review the identified risk factors in the 10-K to understand potential challenges facing RadNet.
3. Examine management's discussion and analysis for insights into the company's strategic priorities and outlook.

Key Dates

• 2023-12-31: Fiscal Year End — Reporting period for the 10-K
• 2024-02-29: Filing Date — Date the 10-K was filed with the SEC

Year-Over-Year Comparison

This filing is the annual 10-K report for the fiscal year ending December 31, 2023, providing a comprehensive update compared to previous filings.

Filing Documents

• rdnt-20231231.htm (10-K) — 2644KB
• ex109-amendmenttoemploym.htm (EX-10.9) — 5KB
• ex1011-amendmenttoemploy.htm (EX-10.11) — 4KB
• ex1013-amendmenttoemploy.htm (EX-10.13) — 4KB
• ex1015-amendmenttoemploy.htm (EX-10.15) — 4KB
• ex1017-amendmenttoemploy.htm (EX-10.17) — 4KB
• ex1019-amendmenttoemploy.htm (EX-10.19) — 4KB
• a10k2023exhibit211.htm (EX-21.1) — 70KB
• a10k2023exhibit231.htm (EX-23.1) — 4KB
• q42023exhibit311.htm (EX-31.1) — 16KB
• q42023exhibit312.htm (EX-31.2) — 17KB
• q42023exhibit321.htm (EX-32.1) — 7KB
• q42023exhibit322.htm (EX-32.2) — 6KB
• ex971-radnetincpolicyonrec.htm (EX-97.1) — 65KB
• ex1011-amendmenttoemploy001.jpg (GRAPHIC) — 194KB
• ex1011-amendmenttoemploy002.jpg (GRAPHIC) — 43KB
• ex1011-amendmenttoemploy003.jpg (GRAPHIC) — 26KB
• ex1013-amendmenttoemploy001.jpg (GRAPHIC) — 194KB
• ex1013-amendmenttoemploy002.jpg (GRAPHIC) — 43KB
• ex1013-amendmenttoemploy003.jpg (GRAPHIC) — 26KB
• ex1015-amendmenttoemploy001.jpg (GRAPHIC) — 194KB
• ex1015-amendmenttoemploy002.jpg (GRAPHIC) — 43KB
• ex1015-amendmenttoemploy003.jpg (GRAPHIC) — 26KB
• ex1017-amendmenttoemploy001.jpg (GRAPHIC) — 193KB
• ex1017-amendmenttoemploy002.jpg (GRAPHIC) — 44KB
• ex1017-amendmenttoemploy003.jpg (GRAPHIC) — 26KB
• ex1019-amendmenttoemploy001.jpg (GRAPHIC) — 194KB
• ex1019-amendmenttoemploy002.jpg (GRAPHIC) — 43KB
• ex1019-amendmenttoemploy003.jpg (GRAPHIC) — 26KB
• ex109-amendmenttoemploym001.jpg (GRAPHIC) — 210KB
• ex109-amendmenttoemploym002.jpg (GRAPHIC) — 72KB
• ex109-amendmenttoemploym003.jpg (GRAPHIC) — 26KB
• rdnt-20231231_g1.jpg (GRAPHIC) — 114KB
• 0001628280-24-008035.txt (&nbsp;) — 17190KB
• rdnt-20231231.xsd (EX-101.SCH) — 92KB
• rdnt-20231231_cal.xml (EX-101.CAL) — 121KB
• rdnt-20231231_def.xml (EX-101.DEF) — 713KB
• rdnt-20231231_lab.xml (EX-101.LAB) — 1220KB
• rdnt-20231231_pre.xml (EX-101.PRE) — 956KB
• rdnt-20231231_htm.xml (XML) — 2152KB

Risk Factors

Item 1A. Risk Factors 15

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 26 Item IC. Cybersecurity 26

Properties

Item 2. Properties 27

Legal Proceedings

Item 3. Legal Proceedings 28

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 28 PART II.

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 29

[Reserved] 31

Item 6. [Reserved] 31

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 32

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 49

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 50

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 92

Controls and Procedures

Item 9A. Controls and Procedures 92

Other Information

Item 9B. Other Information 94

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 97 PART III.

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 94

Executive Compensation

Item 11. Executive Compensation 94

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 94

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 94

Principal Accountant Fees and Services

Item 14. Principal Accountant Fees and Services 94 PART IV.

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 96

Form 10-K Summary

Item 16. Form 10-K Summary 100 i Cautionary Note Regarding Forward-Looking Statements This annual report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements reflect current views about future events and are based on our currently available financial, economic and competitive data and on current business plans. Forward-looking statements can generally be identified by terminology such as "may," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," "assumption" or the negative of these terms or other comparable terminology. Forward looking statements in this annual report include statements or inferences we make about: expectations concerning domestic and global economic conditions, rates of inflation, or changes in interest rates; anticipated trends in our revenues, operating expenses or capital expenditures, and our financial guidance; expected future market acceptance for our products or services, and our competitive strengths in the markets we serve; expected timing and potential impact of regulatory changes affecting our business; our ability to successfully acquire and integrate new businesses, and achieve expected benefits, synergies or operating results from those acquisitions; and economic and costs savings anticipated to be derived from our investment in artificial intelligence and machine learning products and solutions. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to known and unknown risks, uncertainties and other factors that are difficult to predict and out of our control. Our actual results, levels of activity, performance or achievements may be materially different from any future results

Business

Item 1. Business Business Overview We are a leading national provider of diagnostic imaging services in the United States based on number of locations and annual imaging revenue. We have been in business since 1985. Our principal business segment is the provision of diagnostic imaging services. At December 31, 2023, we operated, directly or indirectly through joint ventures with hospitals, 366 imaging centers located in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. Our imaging centers provide physicians with capabilities to facilitate the diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, often reducing the cost and amount of care for patients. Our services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The vast majority of our centers offer multi-modality imaging services, a key point of differentiation from our competitors. Our multi-modality strategy diversifies revenue streams, reduces exposure to reimbursement changes and provides patients and referring physicians one location to serve the needs of multiple procedures. Integral to the imaging center business is our software arm headed by our eRad, Inc. subsidiary, which sells computerized systems that distribute, display, store and retrieve digital images. We seek to develop leading positions in regional markets in order to leverage operational efficiencies. We develop our imaging business through a combination of organic growth and acquisitions. Our scale and density within selected geographies provides close, long-term relationships with key payors, radiology groups and referring physicians. Each of our center-level and regional operations teams is responsible for managing relationships with local physicians and payors, meeting our standards of patient serv

View Full Filing

View this 10-K filing on SEC EDGAR